Coronary/Structural Heart

SUPIRA MEDICAL INITIATES U.S. EARLY FEASIBILITY STUDY (EFS) FOR HIGH-RISK PCI

Company expands clinical program beyond 70 patients already treated in South America FIH and Feasibility Studies. FDA acknowledged potential benefits of the Supira System by granting the company a review pathway under the Breakthrough Device Program. Results from EFS will be used to support submission to FDA for Supira’s pivotal […]

Two-Year Data Proves Vista Cardiac Delivers Faster, More Reliable MRI Scans

PALO ALTO, Calif.–(BUSINESS WIRE)–Vista, a leader in intelligent MRI acquisition software, today announced two-year clinical results showing Vista Cardiac significantly improves workflow efficiency, ensures high-quality and consistent imaging, and scales cardiac MRI (CMR) programs to expand access to more patients. “We’re pleased with the strong data from Brigham and Women’s Hospital validating […]

BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure

November 25, 2024 09:21 AM Eastern Standard Time BURLINGTON, Mass.–(BUSINESS WIRE)–BrioHealth Solutions, Inc., a developer of world-leading technology in ventricular assist systems, announced today it has enrolled its first patients in the U.S. for the INNOVATE Trial of the BrioVAD® System. BrioHealth Solutions announced today the first patients have been enrolled […]

Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies

DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to initiate clinical trials for its lead asset, STM-01, and further advance its innovative pipeline. “We are grateful […]

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

November 25, 2024 03:30 AM Eastern Standard Time LONDON–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): […]